

References

S-236

1. Netland PA, Sarkisian SR, Jr., Moster MR, et al. Randomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT study). *Am J Ophthalmol.* 2014;157(2):433-440.
2. Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM, et al. A Randomized Trial of a Schlemm's Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in Open-Angle Glaucoma. *Ophthalmology.* 2015;122(7):1283-1293.
3. American Glaucoma Society. Position statement on new glaucoma surgical procedures. 2012; http://www.americanglaucomasociety.net/professionals/policy_statements/new_glaucoma_surgical_procedures. Accessed February 6, 2018.
4. Prum BE, Jr., Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma Preferred Practice Pattern((R))guidelines. *Ophthalmology.* Jan 2016;123(1):P41-p111. PMID 26581556. Accessed February 6, 2018.
5. National Institute for Health and Care Evidence (NICE). Trabecular stent bypass microsurgery for open-angle glaucoma [IPG575]. 2017; <https://www.nice.org.uk/guidance/ipg575>. Accessed February 6, 2018.
6. Kotecha A, Feuer WJ, Barton K, et al. Quality of life in the tube versus trabeculectomy study. *Am J Ophthalmol.* 2017; 176:228-235.
7. Wang X, Khan R, Coleman A. Device-modified trabeculectomy for glaucoma. *Cochrane Database Syst Rev.* 2015;12(12):CD010472.
8. Wagschal LD, Trope GE, Jinapriya D, et al. Prospective randomized study comparing Ex-PRESS to trabeculectomy: 1-Year results. *J Glaucoma.* 2015; 27(8):625-9.
9. Gonzalez-Rodriguez JM, Trope GE, Drori-Wagschal L, et al. Comparison of trabeculectomy versus Ex-PRESS: 3-year follow-up. *Br J Ophthalmol.* 2016; 100(9):1269-73.
10. Dib Bustros Y, Fechtner R, S Khouri A. Outcomes of Ex-PRESS and trabeculectomy in a glaucoma population of African origin: One year results. *J Curr Glaucoma Pract.* 2017;11(2):42–47.
11. Omatsu S, Hirooka K, Nitta E, Ukegawa K. Changes in corneal endothelial cells after trabeculectomy and EX-PRESS shunt: 2-year follow-up. *BMC Ophthalmol.* 2018;18(1):243.
12. Budenz DL, Barton K, Gedde SJ, et al. Five-year treatment outcomes in the Ahmed Baerveldt comparison study. *Ophthalmology.* 2015;122(2):308–316.
13. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. *Br J Ophthalmol.* 2017;101(6):130–195.
14. Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma. [IPG612]. 2018; <https://www.nice.org.uk/guidance/ipg612/chapter/1-Recommendations>. Accessed October 3, 2019.

15. Trabecular stent bypass microsurgery for open-angle glaucoma [IPG575]. 2017; <https://www.nice.org.uk/guidance/ipg575>. Accessed October 3, 2019.
16. Prum BE Jr, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern® guidelines. *Ophthalmol*. 2016; 123(1):41-111.
17. Katz LJ, Erb C, Carceller Guillamet A, et al. Long-term titrated IOP control with one, two, or three trabecular micro-bypass stents in open-angle glaucoma subjects on topical hypotensive medication: 42-month outcomes. *Clin Ophthalmol*. 2018;12:255–262.
18. Katz LJ, Erb C, Carceller GA, et al. Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication. *Clin Ophthalmol*. 2015;9:2313–2320.
19. Vold SD, Voskanyan L, Tetz M, et al. Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months [published correction appears in *Ophthalmol Ther*. 2016 Dec;5(2):173]. *Ophthalmol Ther*. 2016;5(2):161–172.
20. De Gregorio A, Pedrotti E, Russo L, Morseli S. Minimally invasive combined glaucoma and cataract surgery: Clinical results of the smallest ab interno gel stent. *Int Ophthalmol*. 2018; 38(3):1129-1134.
21. Fea AM, Ahmed II, Lavis C, et al. Hydrus microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: One year results. *Clin Exp ophthalmol*. 2017; 45(2):120-127.
22. Samuelson TW, Chang DF, Marquis R, et al. A schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract. *Ophthalmol*. 2019; 126(1):29-37.
23. Vlasov A, Kim WI. The Efficacy of Two Trabecular Bypass Stents Compared to One in the Management of Open-Angle Glaucoma. *Military Medicine*. 2017; 182(1):222–225.
24. Donnenfeld ED, Solomon KD, Voskanyan L, et al. A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma. *Clin Ophthalmol*. 2015;9:2057–2065.
25. Ferguson T, Swan R, Ibach M, et al. Evaluation of a trabecular microbypass stent with cataract extraction in severe primary open-angle glaucoma. *J Glaucoma*. 2018; 27(1):71-76.
26. Kurji K, Rudinsky CJ, Rayat JS, et al. Phaco-trabectome verses phaco-iStent in patients with open-angle glaucoma. *Can J Ophthalmol*. 2017; 52(1):99-106.
27. Fea AM, Consolandi G, Zola M, et al. Micro-Bypass Implantation for Primary Open-Angle Glaucoma Combined with Phacoemulsification: 4-Year Follow-Up. *J Ophthalmol*. 2015;2015:795357.
28. Agrawal P, Bradshaw SE. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma. *Ophthalmol Ther*. 2018;7(1):49–73.
29. Mansouri K, Guidotti J, Rao HL, et al. Propective evaluation of standalone XEN gel implant and combined phacoemulsification-XEN gel implant surgery: 1-Year result. *J Glaucoma*. 2018;27(2):140-147.

30. Tan SZ, Walkden A, Au L. One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management. *Eye (Lond)*. 2018;32(2):324–332.
31. Ozal Sa, Kaplaner O, Basar BB, et al. An innovation in glaucoma surgery: XEN45 gel stent implantation. *Arq Bras Offamol*. 2017; 80(6): 382-385.
32. Galal A, Bilgic A, Eltanamly R, Osman A. XEN Glaucoma Implant with Mitomycin C 1-Year Follow-Up: Result and Complications. *J Ophthalmol*. 2017;2017:5457246.
33. Hengerer FH, Kohnen T, Mueller M, et al. Ab interno gel implant for the treatment of glaucoma patients with or without prior glaucoma surgery: 1-year results. *J Glaucoma*. 2017; 26(12):1130-1136.
34. Grovers DS, Flynn WJ, Bashford KP, et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. *Am J Ophthalmol*. 2017; 183:25-36.
35. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. efficacy, safety and risk factors for failure of standalone ab interno gelatin microstent implantation verses standalone trabeculectomy. *Ophthalmol*. 2017; 124(11):1579-1588.
36. Budenz DL, Feuer WJ, Barton K, et al. Postoperative Complications in the Ahmed Baerveldt Comparison Study During Five Years of Follow-up. *Am J Ophthalmol*. 2016;163:75–82.
37. Christakis PG, Kalenak JW, Tsai JC, et al. The Ahmed verses Baerveldt study: Five-year outcomes. *Ophthalmol*. 2016; 123(10): 2093-102.
38. Christakis PG, Zhang D, Budenz DL, et al. Five-year pooled data analysis of the Ahmed Baerveldt comparison study and the Ahmed verses Baerveldt study. 2017; 176:118-126.
39. Bo W, Dai D, Sun F. Observation of curative effects of Ex-PRESS and AGV implantation in the treatment of refractory glaucoma. *Exp Ther Med*. 2018;15(5):4419–4425.